Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B.

Entecavir and Tenofovir Alafenamide Fumarate: Renal Effects in Elderly Hepatitis B Patients

Chronic hepatitis B (CHB) is a serious liver infection that can lead to liver failure. Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are commonly used antiviral medications for CHB, but concerns have been raised about their potential long-term effects on renal function, particularly in elderly patients. This study investigated the effects of ETV and TAF on renal function in elderly Japanese patients with CHB.

Navigating the Desert of Long-Term Effects

The study found that both ETV and TAF were associated with a decline in estimated glomerular filtration rates (eGFR) in elderly patients with CHB. This decline was more pronounced in patients aged 65 years and older compared to younger patients. These findings highlight the importance of careful monitoring of renal function in elderly patients receiving long-term treatment with these antiviral medications.

Ensuring Kidney Health in Elderly Patients

The study underscores the need for close monitoring of renal function in elderly patients receiving long-term antiviral therapy for CHB. Like a camel carefully navigating a desert, we must be mindful of the potential long-term effects of medications and adjust our treatment strategies accordingly. Regular monitoring of renal function and early intervention can help to minimize the risk of kidney damage and ensure the long-term well-being of patients.

Dr.Camel's Conclusion

The study provides important information about the potential renal effects of ETV and TAF in elderly patients with CHB. It underscores the importance of careful monitoring and individualized treatment approaches to ensure the long-term health and well-being of patients. As we navigate the complex world of antiviral therapy, we must be vigilant in our efforts to protect the health of our patients, especially those who are more vulnerable to the potential side effects of medications.